Skip to main content

Table 4 Univariate analyses of factors affecting household transmission of influenza infection

From: Efficacy of baloxavir marboxil on household transmission of influenza infection

Variables

With household transmission (n = 51)

Without household transmission (n = 367)

Odds ratio (95% CI)

P value

Age of household patients (years), n (%)

 0–6

12 (23.5)

35 (9.5)

2.92 (1.40–6.09)

< 0.01

 7–19

7 (13.7)

62 (16.9)

0.93 (0.42–2.08)

0.87

 20–64

27 (52.9)

216 (58.8)

0.77 (0.42–1.38)

0.38

 ≥ 65

5 (9.8)

54 (14.7)

0.63 (0.24–1.66)

0.34

Age of index patients (years), n (%)

 0–6

7 (13.7)

60 (16.3)

0.81 (0.35–1.89)

0.63

 7–19

14 (27.4)

114 (31.1)

0.84 (0.44–1.61)

0.60

 20–64

23 (45.1)

144 (39.2)

1.29 (0.71–2.32)

0.40

 ≥ 65

7 (13.7)

49 (13.4)

1.03 (0.44–2.42)

0.94

Household size, n (%)

 ≤ 3

15 (29.4)

101 (27.5)

1.10 (0.58–2.09)

0.78

 4

22 (43.1)

141 (38.4)

1.22 (0.67–2.20)

0.52

 ≥ 5

14 (27.4)

125 (34.1)

0.73 (0.38–1.41)

0.35

Influenza vaccination in the same eason in household patients, n (%)

18 (35.3)

117 (31.9)

1.17 (0.63–2.16)

0.63

Index patients with baloxavir treatment, n (%)

10 (19.6)

108 (29.4)

0.59 (0.28–1.21)

0.14

Respiratory tract symptoms in index patients, n (%)

23 (45.1)

132 (36.0)

1.46 (0.81–2.64)

0.31

  1. CI Confidence interval